Keyphrases
Tumor Cells
100%
Receptor Tyrosine Kinase
100%
Expression Level
100%
Kinase Inhibition
100%
Cellular Expression
100%
ImmunoPET
100%
Multireceptor
100%
Epidermal Growth Factor Receptor
44%
Protein Level
22%
Tumor Growth
22%
Targeted Therapy
22%
Human Epidermal Growth Factor Receptor 2 (HER2)
22%
Cetuximab
22%
Tumor Resistance
22%
Mitogen-activated Protein Kinase
11%
Renal Cell Carcinoma
11%
Tumor
11%
Patient-derived Xenograft
11%
Tyrosine Kinase
11%
Protein Expression
11%
Cellular Level
11%
Co-expression
11%
Tumor Response
11%
Trastuzumab
11%
Zirconium-89 (89Zr)
11%
Redundancy
11%
Protein Kinase Inhibitors
11%
Trametinib
11%
Protein Kinase B
11%
Extracellular Signal-regulated Kinase Signaling Pathway
11%
Onartuzumab
11%
Hepatocyte Growth Factor Receptor
11%
Panitumumab
11%
Antireceptor
11%
INC280
11%
Medicine and Dentistry
Tumor Cell
100%
Protein Tyrosine Kinase
100%
Immunoglobulin
100%
Phosphotransferase
100%
Polyethylene Terephthalate
100%
Neoplasm
25%
Targeted Therapy
25%
Epidermal Growth Factor Receptor 2
25%
Gamma Urogastrone
25%
Epidermal Growth Factor Receptor
25%
Mitogen-Activated Protein Kinase
25%
Cetuximab
25%
Tumor Resistance
25%
Clear Cell Renal Cell Carcinoma
12%
Phosphoinositide 3-Kinase
12%
Ex Vivo
12%
Protein Expression
12%
Xenograft
12%
Kinase Signaling
12%
Tumor Progression
12%
Cancer Inhibition
12%
Cell Signaling Pathway
12%
Trametinib
12%
Protein Kinase B
12%
Trastuzumab
12%
Zirconium 89
12%
Receptor Tyrosine Kinase
12%
Scatter Factor Receptor
12%
Capmatinib
12%
Panitumumab
12%
Onartuzumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Phosphotransferase
100%
Protein Tyrosine Kinase
100%
Immunoglobulin
100%
Polyethylene Terephthalate
100%
Mitogen Activated Protein Kinase
22%
Epidermal Growth Factor Receptor
22%
Epidermal Growth Factor Receptor 2
22%
Gamma Urogastrone
22%
Cetuximab
22%
Tumor Resistance
22%
Tumor Growth
11%
Phosphatidylinositol 3 Kinase
11%
Renal Cell Carcinoma
11%
Cancer Inhibition
11%
Trastuzumab
11%
Zirconium 89
11%
Protein Kinase B
11%
Trametinib
11%
Capmatinib
11%
Panitumumab
11%
Scatter Factor Receptor
11%
Onartuzumab
11%